ReviewiScience2026
Metabolic reprogramming-mediated therapeutic resistance in renal cell carcinoma: Mechanisms and targeted intervention strategies.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is one of the most frequent urological tumors and exhibits metabolic reprogramming alongside genetic mutations. RCC cells reprogram pathways involved in glucose, lipid, and amino acid metabolism to meet their energy and anabolic demands. In recent years, targeted drugs, immunotherapy, and radiotherapy have significantly improved the prognosis of patients with metastatic RCC. Nevertheless, the development of resistance remains a major cause of treatment failure and disease progression in metastatic RCC. A deeper understanding of the metabolic mechanisms underlying therapy resistance is critical for refining therapeutic strategies. The molecular mechanism of metabolic reprogramming involved in therapy resistance is comprehensively discussed. Novel strategies for overcoming therapy resistance of RCC are proposed, including the development of new drugs targeting metabolism, nanoparticles co-loaded with anti-tumor drugs, the application of combination therapies, and personalized medicine approaches. In conclusion, this review provides a thorough overview of metabolic alterations in RCC and their role in therapy resistance, highlighting the potential for developing new treatments for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.